Natco Pharma shares fall 3.5% as SC agrees to urgently list Roche's plea on Risdiplam launch

Natco Pharma shares fall 3.5% as SC agrees to urgently list Roche's plea on Risdiplam launch

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of Natco Pharma fell 3.5% on October 14 as Supreme Court agreed to urgently list Swiss pharama giant Roche's plea on Risdiplam launch.

Roche moved the apex court after Delhi High Court allowed Natco Pharma to launch Risdiplam drug.

Roche's plea against Natco Pharma to be listed either on October 16 or 17, said Supreme Court on October 14.

At 12:20 pm on October 14, Natco Pharma shares on NSE were trading 3.5% lower at Rs 808.7 apiece.

Delhi High Court recently dismissed Roche's appeal and allowed the Indian company to sell the spinal muscular atrophy (SMA) drug Risdiplam in India.

Roche had filed an appeal at the High Court against a single-judge order passed in March 2025 that had denied an injunction on Natco's sale of the drug in India.

The previous order had noted that the life-saving therapy must remain affordable and accessible. The March order had paved the way for Natco to launch the generic version of Roche's 'Risdiplam' drug.

The single judge bench had factored the challenge of invalidity of Roche's patent and laid special emphasis on the public interest, considering the Swiss company's pricing had rendered the drug inaccessible and unaffordable to the bulk of its patients, Natco said in a statement.

After the division bench of the Delhi High Court dismissed Roche's appeal, Natco said that it has decided to launch the product with immediate effect at an MRP of Rs 15,900. "The Company also intends to offer some discount to certain deserving patients through its patient access programme," it added.